iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapyNEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy” in Frontiers in Immunology. The publication, aut ...

Core Insights - MiNK Therapeutics, Inc. is experiencing a significant increase in stock price, with INKT stock rising 471.3% to $44.16 [7] - The company is focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, with promising clinical results reported [2] Clinical Developments - A landmark case published in Nature's Oncogene reported a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer after receiving a single infusion of agenT-797 combined with Bristol-Myers Squibb's Opdivo [2][3] - The patient showed no evidence of disease over two years, with donor iNKT cells detectable for up to six months post-infusion, and the treatment was well-tolerated without severe side effects [4] - Data from a Phase 2 trial in 2L gastric cancer presented at the 2025 AACR Immuno-Oncology meeting indicated immune activation and early signs of tumor control in patients previously resistant to checkpoint inhibitors, with some patients surviving beyond 12 months [5] - A separate peer-reviewed case report noted a patient with metastatic gastric cancer achieving a 42% tumor reduction and over nine months of progression-free survival following a single infusion of agenT-797 combined with nivolumab [6] Market Activity - The trading volume for INKT stock reached 20.2 million, significantly higher than the average volume of 7.5 million [1]

Core Insights - MiNK Therapeutics has published a significant case study demonstrating the efficacy of its allogeneic iNKT cell therapy, agenT-797, in achieving complete and durable remission in a patient with metastatic testicular cancer who had previously failed multiple treatments [1][2][3] Group 1: Clinical Evidence - The case study published in Nature's Oncogene details a patient who achieved complete clinical, radiologic, and biochemical remission after receiving a single infusion of agenT-797 alongside nivolumab, with no evidence of disease over two years later [2] - The patient had previously undergone multiple lines of therapy, including platinum-based chemotherapy and various immune checkpoint inhibitors, highlighting the potential of iNKT cell therapy in heavily pre-treated patients [2][3] - MiNK presented additional data at the 2025 AACR Immuno-Oncology meeting, showing immune activation and early signals of tumor control in patients with gastric cancer who were previously refractory to checkpoint inhibitors [3][4] Group 2: Mechanism and Development - AgenT-797 is designed to harness both innate and adaptive immunity, functioning as a "master regulator" that combines the cytotoxic capabilities of NK cells with T-cell-like antigen recognition [7] - The therapy is scalable and off-the-shelf, aimed at providing accessible treatment options for patients with solid tumors and severe pulmonary inflammation [8] - MiNK is actively enrolling patients in an ongoing Phase 2 trial for gastric cancer, with further readouts expected in the coming months [4]

因消息面利好，医疗器械近日受到关注。同类费率最低档的医疗器械ETF基金（159797）受冲高回落跌0.54%，盘中一度涨近2%， 持续溢价交易，近5日有3日"吸金"，今日盘中再度净流入！ 消息面上，国监局网站7月3日消息，日前，药监局发布优化全生命周期监管支持高端医疗器械创新发展的有关举措。该举措涵盖优 化特殊审批程序、完善分类和命名原则等十个方面的内容，旨在全力支持高端医疗器械重大创新，促进新技术、新材料、新工艺和 新方法在医疗健康领域的应用，满足人民群众健康需求，提升我国高端医疗器械的国际竞争力。 此外，高层发布通知，决定7月6日起，在行政采购活动中对部分自欧盟进口的医疗器械采取相关措施：采购人采购预算金额4500万 元人民币以上的医疗器械时，确需采购进口产品的，在履行法定程序后，应当排除欧盟企业（不包括在华欧资企业）参与；对于参 与的非欧盟企业，其提供的自欧盟进口的医疗器械占比不得超过项目合同总金额的50%；上述措施不适用于仅自欧盟进口的医疗器 械能够满足采购需求的采购项目。 医疗器械ETF基金（159797）标的指数成分股多数飘绿：热景生物跌超5%，迈瑞医疗跌超2%，乐普医疗、贝瑞基因跌超1%。上涨 ...

出品丨虎嗅汽车组 作者丨李赓 头图丨视觉中国 从历史经验看，高通在特定赛道的表现，最终"决定权"往往不在自己手里：在智能手机的黄金十年，是三星、小米们的极致探索，成就了骁龙的霸主地 位；而在PC市场，微软与传统软件生态的步调迟疑，也让高通的Windows on ARM战略至今未能真正突破。 当战场转移至智能汽车，"决定者"的角色再次出现，顺势落在了中国汽车行业众多的智驾参与者头上。 中国智驾伙伴，推着高通往前走 6月底，高通再次在苏州举办了"汽车技术与合作峰会"。 在这场活动上，一幅完整的中国智能汽车产业图谱被精准地呈现出来。与会者名单本身就是一份宣言：从零跑、上汽通用、北汽等整车厂，到卓驭、 Momenta、元戎启行与博世这样的核心一级供应商 （Tier1） ，再到几乎覆盖所有细分领域的软件合作伙伴，高通的座上宾囊括了产业链的每一个关键 角色。 然而，与智能手机时代高通定义行业范式、引领技术演进的"固定模式"不同，进入智能驾驶时代：中国合作伙伴的力量变得更加强大，反倒成为了整个 生态的主要推动者。 一个最明显的迹象，在于一众中国合作伙伴在实际解决方案打造过程中的引领作用。 举一个核心例子。 此前，高通汽车业 ...

Group 1: Core Insights - The strategic value of state-owned enterprises (SOEs) is being redefined amid a sluggish global economic recovery and deep domestic economic adjustments [1] - Public funds are rapidly increasing their investment in SOEs, with the total scale of SOE-related funds exceeding 300 billion yuan in 2023 [1] - The investment logic is shifting from single low valuation to a dual drive of high dividends and hard technology [1] Group 2: Policy and Industry Trends - The dual forces of policy catalysis and industrial upgrading are reshaping the valuation system of SOEs, with a projected asset scale of central enterprises exceeding 90 trillion yuan in 2024, a 5.9% year-on-year increase [2] - Strategic emerging industry investments reached 2.7 trillion yuan in 2024, marking a 21.8% increase and surpassing 40% of total investments for the first time [2] - New index tools like the CSI Central Enterprise Innovation-Driven Index and the CSI National New Central Enterprise Modern Energy Index have emerged to cover core assets in technology innovation and green transformation [2][4] Group 3: Fund Performance and Strategy - The CSI Central Enterprise Innovation-Driven Index has a 12-month dividend yield of 3.59%, outperforming several major indices [3] - The CSI National New Central Enterprise Modern Energy Index has shown superior performance and risk-return ratios compared to major broad-based indices since its inception [4] - The BoShi Fund's Central Enterprise Innovation-Driven ETF has achieved net value growth rates of 4.06%, 19.89%, and 66.24% over the past year, three years, and five years, respectively, all exceeding benchmark returns [5] Group 4: Investment Philosophy and AI Integration - BoShi Fund emphasizes a "strategic account prioritizing financial account" investment philosophy, recognizing the potential for value re-evaluation of traditional resource factors [8] - The company has initiated AI technology exploration since 2018, establishing an AI laboratory in 2023 to enhance its investment research capabilities [9] - AI-driven investment research is expected to create differentiated alpha factors and improve investment decision-making accuracy [10]

Core Insights - Qualcomm's historical performance in specific sectors often depends on external players, as seen in the smartphone era where companies like Samsung and Xiaomi propelled Snapdragon's dominance [1] - In the smart automotive sector, the decision-making power has shifted to numerous Chinese automotive participants, indicating a change in the ecosystem dynamics [2][8] Group 1: Qualcomm's Position in the Automotive Industry - Qualcomm hosted an "Automotive Technology and Cooperation Summit" in Suzhou, showcasing a comprehensive map of the Chinese smart automotive industry with key players from various segments [6][7] - Unlike the smartphone era where Qualcomm defined industry standards, in the smart driving era, Chinese partners have become the main drivers of the ecosystem, leading in the development of practical solutions [8] - The recent Snapdragon 8797 chip represents a shift from Qualcomm's previous product positioning, serving as a flexible "integrated central computing platform" rather than a purely smart driving chip [12] Group 2: Competitive Landscape and Market Dynamics - The Snapdragon 8797 chip boasts an estimated sparse equivalent computing power exceeding 700 TOPS, meeting the performance needs for both cockpit and smart driving applications [13] - Chinese partners are pushing for stronger AI performance, with some opting to use the more powerful 8797 chip for cockpit solutions instead of the newly released 8397 [14][15] - Xiaomi's approach is notably radical, integrating the consumer-grade Snapdragon 8 Gen 3 chip into the cockpit and deeply combining it with NVIDIA's Thor chip, highlighting a trend towards cross-brand chip integration [17][22] Group 3: Market Challenges and Opportunities - Qualcomm's product rollout speed is not industry-leading, with the Snapdragon 8797 expected to enter mass production in early 2026, lagging behind competitors [23] - Despite challenges in software support compared to NVIDIA, Qualcomm's partners can leverage their capabilities to fill gaps, allowing Qualcomm to focus on chip design and production [25] - The current market landscape shows that Qualcomm's mid-tier products, such as the 8620 and 8650, are gaining traction as mainstream options, driven by the cost-effectiveness of combining Qualcomm hardware with Chinese partners' software [26][28] Group 4: Innovation and Strategic Shifts - The intense competitive environment in China is fostering innovation, compelling all participants, including chip giants, to adopt more agile and market-responsive development models [34] - Major global players are increasingly focusing on the Chinese market, with strategies evolving to operate independently within China while developing competitive products for the global market [36] - The collaboration between companies like GAC Toyota and local partners such as Huawei and Xiaomi signifies a broader trend of integrating local resources to enhance competitiveness in the automotive sector [35]

Group 1 - The medical device sector is experiencing strong performance, with the medical device ETF (159797) rising by 1.08% and attracting net inflows for the second consecutive day [1][3] - The majority of the constituent stocks of the medical device ETF saw gains, with notable increases such as Hotgen Biotech rising over 11%, and Xiangyu Medical and Xinmai Medical both increasing over 8% [3] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, which includes enhancing the use of medical insurance data for drug research and improving the dynamic adjustment mechanism for the basic medical insurance drug list [3] Group 2 - The release of the RuiPath pathology model by Ruijin Hospital marks a significant advancement in domestic medical AI, transitioning from technical breakthroughs to ecosystem sharing [4] - The measures approved by the National Medical Products Administration aim to optimize the lifecycle regulation to support the innovation of high-end medical devices, including improving special approval processes and enhancing communication mechanisms [5] - The external skeleton robot industry is viewed positively due to recent technological breakthroughs and product innovations, with applications in both medical and industrial sectors expected to grow rapidly [6][7] Group 3 - The medical device ETF (159797) encompasses a wide range of medical equipment and diagnostics, with the top ten weighted stocks accounting for nearly 47% of the fund [7][8] - The top holdings in the medical device ETF include Mindray Medical (14.65%), United Imaging Healthcare (9.44%), and Aimeike (3.95%) among others [8]

Core Insights - Sanofi has decided to advance Kymera's next-generation oral IRAK4 degrader candidate, KT-485, into clinical testing while not proceeding with KT-474 [1][3] - KT-485 has shown increased selectivity and potency with a favorable safety profile in preclinical testing [1][5] - Kymera is eligible for up to $975 million in collaboration milestones and has achieved a $20 million milestone related to preclinical activities for KT-485 [4][6] Company and Product Development - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [2][7] - KT-485, also known as SAR447971, is a first-in-class oral IRAK4 degrader aimed at treating immuno-inflammatory diseases [6] - The collaboration with Sanofi includes a 50/50 development and profit share option for KT-485 in the U.S. [1][4] Clinical and Market Potential - The advancement of KT-485 into Phase 1 testing is expected next year, reflecting its compelling preclinical profile [3][5] - The IRAK4 pathway is targeted due to its role as a master regulator of innate immunity, which could lead to a broad anti-inflammatory effect [6] - The collaboration aims to transform treatment paradigms in immunology by leveraging the unique properties of degraders compared to traditional small molecule inhibitors [5]

业绩方面，受政策、消费等因素影响，中信建投预计医疗器械板块Q2整体业绩仍有所承压。细分板块来看：（1）预计医疗设备行业招标数据持续 改善，部分公司Q2或Q3将实现高增长；（2）高值耗材板块预计手术量缓慢复苏，板块内各公司业绩趋势分化较大，集采出清或新品放量的公司有 望实现高增长；（3）IVD板块仍受DRG、集采、医疗服务价格调整等因素影响。 但值得注意的是，医疗器械板块内仍有结构性的投资机会：部分公司Q2有望实现高增长，Q3出现重大拐点；部分公司全年业绩高增长的确定性较 强，AI医疗、脑机接口等新技术方向有望产生持续催化。此外，国产医疗器械持续创新，部分创新产品获批进度或临床数据全球领先，具有license- out可能性。（来源：中信建投20250602《医疗器械行业观点更新：短期业绩承压，结构性机会仍在》） 【机构：中美关系边际缓和有利于医疗设备降低生产成本】 湘财证券指出，中美关税边际缓和有利于医疗设备降低生产成本，扩大海外市场份额。近年来国内企业在高端设备、介入治疗、诊断试剂等领域不 断突破，逐步替代进口产品。然而，由于部分关键零部件、检测设备仍依赖进口，关税波动曾对企业的成本结构和利润空间构成压力。 ...